GB0526552D0 - New use - Google Patents

New use

Info

Publication number
GB0526552D0
GB0526552D0 GB0526552A GB0526552A GB0526552D0 GB 0526552 D0 GB0526552 D0 GB 0526552D0 GB 0526552 A GB0526552 A GB 0526552A GB 0526552 A GB0526552 A GB 0526552A GB 0526552 D0 GB0526552 D0 GB 0526552D0
Authority
GB
United Kingdom
Prior art keywords
new use
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0526552A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morvus Technology Ltd
Original Assignee
Morvus Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morvus Technology Ltd filed Critical Morvus Technology Ltd
Priority to GB0526552A priority Critical patent/GB0526552D0/en
Publication of GB0526552D0 publication Critical patent/GB0526552D0/en
Priority to CA2635388A priority patent/CA2635388C/en
Priority to CN201310241391.1A priority patent/CN103315995B/zh
Priority to CN201710224938.5A priority patent/CN107080746B/zh
Priority to EP06831498A priority patent/EP1951213B1/en
Priority to EP10075381.3A priority patent/EP2258430B1/en
Priority to PCT/GB2006/004947 priority patent/WO2007074344A1/en
Priority to MX2008008616A priority patent/MX2008008616A/es
Priority to NZ56948306A priority patent/NZ569483A/xx
Priority to CN201410341330.7A priority patent/CN104188943B/zh
Priority to US12/159,363 priority patent/US9029569B2/en
Priority to CN200680053566.4A priority patent/CN101389320B/zh
Priority to JP2008548029A priority patent/JP5368803B2/ja
Priority to ES10075381.3T priority patent/ES2623857T3/es
Priority to AU2006329678A priority patent/AU2006329678B2/en
Priority to KR20087018577A priority patent/KR20080091354A/ko
Priority to ES06831498T priority patent/ES2399288T3/es
Priority to RU2008131054/15A priority patent/RU2445078C2/ru
Priority to CA2826746A priority patent/CA2826746C/en
Priority to NO20082852A priority patent/NO20082852L/no
Priority to IL192507A priority patent/IL192507A0/en
Priority to RU2011146556/15A priority patent/RU2011146556A/ru
Priority to JP2013015431A priority patent/JP5699170B2/ja
Priority to US14/628,980 priority patent/US9907784B2/en
Priority to HK15104794.3A priority patent/HK1204269B/xx
Priority to US15/875,230 priority patent/US10398676B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/02—Treatment of flour or dough by adding materials thereto before or during baking by adding inorganic substances
    • A21D2/06—Reducing agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B31/00—Reduction in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Mechanical Engineering (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB0526552A 2005-12-29 2005-12-29 New use Ceased GB0526552D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GB0526552A GB0526552D0 (en) 2005-12-29 2005-12-29 New use
CA2826746A CA2826746C (en) 2005-12-29 2006-12-29 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide
JP2008548029A JP5368803B2 (ja) 2005-12-29 2006-12-29 α−ヒドロキシカルボニル化合物の還元剤としての使用
AU2006329678A AU2006329678B2 (en) 2005-12-29 2006-12-29 Use of alpha-hydroxy carbonyl compounds as reducing agents
CN201710224938.5A CN107080746B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂
EP06831498A EP1951213B1 (en) 2005-12-29 2006-12-29 Use of alpha-hydroxy carbonyl compounds as reducing agents
EP10075381.3A EP2258430B1 (en) 2005-12-29 2006-12-29 5-(Aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide and its use in medicine
PCT/GB2006/004947 WO2007074344A1 (en) 2005-12-29 2006-12-29 Use of alpha-hydroxy carbonyl compounds as reducing agents
MX2008008616A MX2008008616A (es) 2005-12-29 2006-12-29 Uso de compuestos de alfa-hidroxi carbonilo como agentes reductores.
NZ56948306A NZ569483A (en) 2005-12-29 2006-12-29 Use of alpha-hydroxy carbonyl compounds as reducing agents
CN201410341330.7A CN104188943B (zh) 2005-12-29 2006-12-29 使用α‑羟基羰基化合物作为还原剂
US12/159,363 US9029569B2 (en) 2005-12-29 2006-12-29 Use of alpha-hydroxy carbonyl compounds as reducing agents
CN200680053566.4A CN101389320B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂
CA2635388A CA2635388C (en) 2005-12-29 2006-12-29 Use of alpha-hydroxy carbonyl compounds as reducing agents
ES10075381.3T ES2623857T3 (es) 2005-12-29 2006-12-29 5-(Aziridin-1-il)-4-hidroxilamin-2-nitrobenzamida y su uso en medicina
CN201310241391.1A CN103315995B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂
KR20087018577A KR20080091354A (ko) 2005-12-29 2006-12-29 알파-히드록시 카르보닐 화합물의 환원제로서의 용도
ES06831498T ES2399288T3 (es) 2005-12-29 2006-12-29 Uso de compuestos de alfa-hidroxicarbonilo como agentes reductores
RU2008131054/15A RU2445078C2 (ru) 2005-12-29 2006-12-29 Применение альфа-гидроксикарбонильных соединений в качестве восстанавливающих веществ
NO20082852A NO20082852L (no) 2005-12-29 2008-06-27 Faramsoytisk blanding samt bruk av alfa-hydroksy karbonylforbindelser som reduksjonsmidler
IL192507A IL192507A0 (en) 2005-12-29 2008-06-29 Use of alpha-hydroxy carbonyl compounds as reducing agents
RU2011146556/15A RU2011146556A (ru) 2005-12-29 2011-11-16 Применение 5-(азаридин-1-ил)-4-гидроксиламино-2нитробензамида в качестве лекарственного средства для борьбы с нежелательным ростом или пролиферацией клеток
JP2013015431A JP5699170B2 (ja) 2005-12-29 2013-01-30 α−ヒドロキシカルボニル化合物の還元剤としての使用
US14/628,980 US9907784B2 (en) 2005-12-29 2015-02-23 Use of alpha-hydroxy carbonyl compounds as reducing agents
HK15104794.3A HK1204269B (en) 2005-12-29 2015-05-20 Use of alpha-hydroxy carbonyl compounds as reducing agents
US15/875,230 US10398676B2 (en) 2005-12-29 2018-01-19 Use of alpha-hydroxy carbonyl compounds as reducing agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0526552A GB0526552D0 (en) 2005-12-29 2005-12-29 New use

Publications (1)

Publication Number Publication Date
GB0526552D0 true GB0526552D0 (en) 2006-02-08

Family

ID=35841324

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0526552A Ceased GB0526552D0 (en) 2005-12-29 2005-12-29 New use

Country Status (15)

Country Link
US (3) US9029569B2 (cg-RX-API-DMAC7.html)
EP (2) EP2258430B1 (cg-RX-API-DMAC7.html)
JP (2) JP5368803B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080091354A (cg-RX-API-DMAC7.html)
CN (4) CN107080746B (cg-RX-API-DMAC7.html)
AU (1) AU2006329678B2 (cg-RX-API-DMAC7.html)
CA (2) CA2826746C (cg-RX-API-DMAC7.html)
ES (2) ES2399288T3 (cg-RX-API-DMAC7.html)
GB (1) GB0526552D0 (cg-RX-API-DMAC7.html)
IL (1) IL192507A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008008616A (cg-RX-API-DMAC7.html)
NO (1) NO20082852L (cg-RX-API-DMAC7.html)
NZ (1) NZ569483A (cg-RX-API-DMAC7.html)
RU (2) RU2445078C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007074344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
EP2534957B1 (en) 2007-12-14 2015-05-27 AeroDesigns, Inc Delivering aerosolizable products
AU2009304542A1 (en) * 2008-10-15 2010-04-22 Xingnong Wang Use of tetrose to inhibit cancer and to increase cell viability
US20110216880A1 (en) * 2010-03-05 2011-09-08 General Electric Company System and method for molecular breast imaging
WO2011163671A2 (en) * 2010-06-25 2011-12-29 Boston Polymer Llc Environmentally benign plasticizers based on derivatives of acetone

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3208999A (en) 1964-09-09 1965-09-28 Nat Starch Chem Corp Preparation of non-inhibited starch amines
US3658788A (en) * 1969-06-06 1972-04-25 Salk Inst For Biological Studi Aminooxazolines and products thereof and processes for synthesizing same
US3711602A (en) * 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
JPS52145523A (en) 1976-05-28 1977-12-03 Kouki Yagishita Antiitumor agent
DE2730720C2 (de) 1977-07-07 1979-07-12 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von praktisch reinem l-Amino-8-nitro-43dihydroxy-anthrachinon
CA1089763A (en) 1978-10-30 1980-11-18 Willard J. Johnson Rodenticide comprising 6-aminonicotinamide and 6- aminonicotinohydroxamic acid
CS204501B1 (en) 1978-11-06 1981-04-30 Miroslav Dub Shaped trap for regulation of the numbers of exoantropous and hemisynantropous rodents classes
US4375394A (en) * 1982-03-11 1983-03-01 Eastman Kodak Company Electrolytic process for the preparation of ethylene glycol and glycerine
ATE66375T1 (de) * 1984-10-05 1991-09-15 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB8804068D0 (en) 1988-02-22 1988-03-23 Roberts J R Improvements relating to control of neoplastic tissue growth
CH680180B5 (cg-RX-API-DMAC7.html) * 1988-07-29 1993-01-15 Ciba Geigy Ag
DE3833194A1 (de) 1988-09-30 1990-04-05 Basf Ag Verfahren zum faerben von textilen materialien aus cellulosefasern
DE4103639A1 (de) * 1991-02-07 1992-08-13 Basf Ag Verfahren zum faerben von textilen materialien aus cellulosefasern
JP4115514B2 (ja) 1991-10-23 2008-07-09 キャンサー・リサーチ・キヤンペーン・テクノロジー・リミテツド Cb 1954およびその類似体を細胞障害性の形態に還元するための細菌のニトロリダクターゼ
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
DE4425436A1 (de) 1994-07-19 1996-01-25 Basf Ag Verfahren zur Herstellung von Acyloinen
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
US5632782A (en) 1994-09-01 1997-05-27 Clariant Finance (Bvi) Ltd. Exhaust dyeing process for sulphur dyes
US20040053208A1 (en) 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
WO1997023456A1 (en) 1995-12-21 1997-07-03 British Technology Group Ltd. Indoloquinone derivatives as bioreductive agents
NZ336381A (en) * 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
JP2001512425A (ja) 1997-02-11 2001-08-21 セラマーク・リミテッド 薬物ターゲティング
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB2365338B (en) 1997-06-14 2002-04-03 Enzacta R & D Ltd Therapeutic systems
US6159706A (en) 1997-12-23 2000-12-12 Newbiotics, Inc. Application of enzyme prodrugs as anti-infective agents
JP2002516304A (ja) 1998-05-22 2002-06-04 シオノギ・バイオリサーチ・コーポレーション 生体還元性細胞傷害剤
JP2002523382A (ja) 1998-08-19 2002-07-30 ザ・ビクトリア・ユニバーシテイ・オブ・マンチエスター 薬物ターゲティング
HK1049443A1 (zh) * 1999-11-12 2003-05-16 Angiotech Pharmaceuticals, Inc. 用放射活性疗法和细胞循环抑制剂联合治疗疾病的组合物和方法
AU783128B2 (en) 2000-03-02 2005-09-29 Innovata Plc TCF responsive element
CN1437594A (zh) * 2000-06-22 2003-08-20 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
DE10049468A1 (de) 2000-10-06 2002-04-11 Bayer Ag N-Alkoxyalkyl-substituierte Benzimidazole, ihre Herstellung und ihre Verwendung als Mittel gegen parasitäre Protozoen
DK1355566T3 (da) * 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
GB0223696D0 (en) 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
GB0313604D0 (en) * 2003-06-12 2003-07-16 Britannia Pharmaceuticals Ltd Delivery device for powdered medicament
DE102004009434A1 (de) * 2004-02-24 2005-12-15 Boehringer Ingelheim International Gmbh Zerstäuber
FR2871697B1 (fr) 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
CA2570245A1 (en) 2004-07-02 2006-01-12 Warner-Lambert Company Llc Compositions and methods for treating pathological infections
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use

Also Published As

Publication number Publication date
CA2635388A1 (en) 2007-07-05
US20100104515A1 (en) 2010-04-29
AU2006329678A1 (en) 2007-07-05
ES2623857T3 (es) 2017-07-12
JP5368803B2 (ja) 2013-12-18
EP2258430A2 (en) 2010-12-08
JP2009522244A (ja) 2009-06-11
RU2011146556A (ru) 2013-05-27
MX2008008616A (es) 2008-11-27
CN101389320B (zh) 2016-02-03
IL192507A0 (en) 2009-08-03
US20180140575A1 (en) 2018-05-24
US10398676B2 (en) 2019-09-03
JP2013116904A (ja) 2013-06-13
JP5699170B2 (ja) 2015-04-08
EP1951213B1 (en) 2012-11-14
CN107080746B (zh) 2021-08-06
NZ569483A (en) 2012-09-28
WO2007074344A8 (en) 2007-12-27
CN101389320A (zh) 2009-03-18
US9029569B2 (en) 2015-05-12
CA2826746A1 (en) 2007-07-05
CN104188943B (zh) 2017-04-12
CA2826746C (en) 2016-08-16
KR20080091354A (ko) 2008-10-10
CA2635388C (en) 2016-08-16
RU2008131054A (ru) 2010-02-10
EP1951213A1 (en) 2008-08-06
AU2006329678B2 (en) 2013-05-09
ES2399288T3 (es) 2013-03-27
EP2258430A3 (en) 2011-06-08
WO2007074344A1 (en) 2007-07-05
CN107080746A (zh) 2017-08-22
CN104188943A (zh) 2014-12-10
RU2445078C2 (ru) 2012-03-20
NO20082852L (no) 2008-09-29
CN103315995B (zh) 2019-03-15
EP2258430B1 (en) 2017-03-22
CN103315995A (zh) 2013-09-25
US20150231113A1 (en) 2015-08-20
US9907784B2 (en) 2018-03-06
HK1204269A1 (en) 2015-11-13

Similar Documents

Publication Publication Date Title
GB0522715D0 (en) New use
DE502005007477D1 (en) Delta-sigma-modulator
GB0505954D0 (en) Novel use
GB0511190D0 (en) Use
GB0520176D0 (en) Use
GB0506001D0 (en) Novel use
GB0506800D0 (en) New uses
GB0526031D0 (en) Use
GB0502250D0 (en) Use
GB0526032D0 (en) Use
EP1846443A4 (en) NEW USE
DE502006002219D1 (en) Rotationspumpe
DE502006007734D1 (en) Thiazolcarbonsäureanilide
DE502006004337D1 (en) Strangführungsrolle
GB0508924D0 (en) New use
GB0515817D0 (en) New use
GB0503950D0 (en) Use
GB0507874D0 (en) Use
GB0503949D0 (en) Use
GB0507986D0 (en) Use
GB0521271D0 (en) Novel use
GB0510592D0 (en) Novel use
GB0506000D0 (en) Novel use
GB0510591D0 (en) Novel use
GB0521273D0 (en) Novel use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)